PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Large-scale population analysis confirms reassuring safety profile of tirzepatide

Analysis of real-world evidence from the FDA adverse event reporting system database finds tirzepatide has similar gastrointestinal tolerability to other GLP-1 medications, without increased risk of diabetic retinopathy, medullary thyroid cancer, or pancr

2024-09-11
(Press-News.org) As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged. Now real-world evidence from the FDA Adverse Event Reporting System (FAERS) database reveals a reassuring safety profile for tirzepatide (TZP).

The findings to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), and published in the The Journal of Endocrinological Investigation (link below) reveal that, compared to the widely used class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), TZP has similar gastrointestinal (GI) tolerability, without increased risk of pancreatitis, diabetic retinopathy (vision loss in T2D caused by damage to the blood vessels in the retina) and medullary thyroid cancer.

“Tirzepatide has shown unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity. Now, our real-world study confirms its reassuring safety profile compared to other GLP-1 RAs such as semaglutide,” said lead author Dr Irene Caruso from the University of Bari Aldo Moro in Italy.

GLP-1 RAs, a group of drugs used to treat T2D, are increasingly used to manage obesity by reducing appetite and slowing gastric emptying.

TZP, a newer dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), has shown even greater weight loss, crucial for reducing the risk of T2D and improving health outcomes in those with obesity or T2D.

Randomised controlled trials have shown the safety profile of TZP to be similar to that of GLP-1RAs, and mainly characterised by adverse GI events.

However, concerns about TZP’s potential link to diabetic retinopathy, pancreato-biliary disorders (diseases affecting the pancreas, gallbladder, and bile ducts), and medullary thyroid cancer have arisen, but evidence is still lacking and inconclusive.

To find out more, researchers mined the FAERS post-marketing surveillance database—that includes reports from manufacturers, patients, and health professionals—to find out whether the same safety concerns emerged from real world experiences.

Researchers retrieved reports of adverse events for TZP related to GI disorders, pancreatitis, cholecystitis (gallbladder inflammation) and cholelithiasis (gallstones), diabetic retinopathy, and thyroid neoplasms.

A reporting odds ratio (ROR) was calculated to assess the disproportionality of reporting of certain adverse event associated with TZP in comparison to any other drug.

The analysis was then filtered for reports concerning age, gender, and the designated primary suspect drug [1]. Adverse event occurrence with TZP was also compared to other diabetes treatments, including insulin, SGLT-2 inhibitors, metformin, and GLP-1RAs (both individually and as a class).

Out of the 20,409 reports referring to 1,432 adverse events, the researchers analysed 7,460 reports, referring to 286 selected adverse events (GI, pancreato-biliary, eye-related and thyroid cancer), of which 22 showed a disproportionality signal.

Disproportionate reporting of several adverse GI events was detected with TZP. Specifically, reports of eructation (burping) were 30 times more likely with TZP compared to other drugs, while nausea, dyspepsia (indigestion), constipation, and pancreatitis were four times more likely to be reported with TZP compared to all other drugs.

However, TZP was associated with a similar risk of GI adverse events as other GLP-1RAs, with some differences including a lower risk of nausea and a greater risk of constipation. As expected, TZP exhibited a greater risk of most GI adverse events compared to insulin and SGLT-2 inhibitors.

No disproportionate reporting of pancreatitis with TZP was found compared to SGLT-2 inhibitors, but a greater risk was described compared to insulin and a lower risk reported versus GLP-1RAs.

Researchers also identified disproportionate reporting of medullary thyroid cancer with TZP, with 13 times greater odds compared to all other drugs (based on three events). However, TZP was associated with a similar risk of medullary thyroid cancer as other GLP-1RAs and SGLT-2 inhibitors, and a greater risk compared to insulin.

Similarly, reports of diabetic retinopathy (based on 12 diabetic retinopathy events) were over three times more likely with TZP compared to all other drugs. But TZP showed a similar risk to SGLT-2 inhibitors and a consistently lower risk compared with GLP-1RAs and insulin.

No disproportionate reporting of gallbladder and biliary-related adverse events was found, except for an increased risk of biliary colic compared to all other drugs and insulin. A similar risk of biliary colic was reported in comparison to GLP-1RAs and SGLT-2i.  

The identified associations were confirmed when restricting the analysis to the designated primary suspect drug, TZP. “An increasing number of people are living with type 2 diabetes and obesity, and understanding which medications can effectively manage these conditions and prevent severe side effects is crucial for their health and quality of life,” said Dr Caruso.

She added: “Our finding suggests that tirzepatide could potentially have a similar if not improved      a safety profile compared to GLP-1RAs. However, the study is limited by its observational nature, the relatively short experience with tirzepatide in everyday clinical use, non-randomised comparisons, potential data incompleteness and duplication, demanding a cautious approach to their interpretation.”

END


ELSE PRESS RELEASES FROM THIS DATE:

Tirzepatide associated with greater weight loss in women than men

2024-09-11
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). The post hoc analysis, which included the four SURMOUNT trials [1], compared tirzepatide with a placebo for up to 72 to 88 weeks in 4,677 adults (2,999 females, 1,678 males) living with obesity, highlighting potential sex differences in the response. Tirzepatide, a once-weekly glucose-dependent ...

Rapid control of blood sugar levels in women with gestational diabetes can reverse the risk of their children developing obesity, US study finds

2024-09-11
Swiftly achieving glycaemic control after a diagnosis of gestational diabetes can bring the baby’s risk obesity in childhood down to a level similar to that of children whose mothers did not have gestational diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found. Gestational diabetes, a type of diabetes that can develop during pregnancy, affects 14% of pregnant women globally and is becoming more common, with those who are living with obesity, have a family ...

Semaglutide’s cardiovascular benefits are maintained in people with impaired kidney function

2024-09-11
The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). The results are based on a pre-specified analysis of the SELECT trial which found that adults with overweight or obesity but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of MACE or ...

Study reveals key predictors for achieving and sustaining blood glucose control and weight loss with tirzepatide in adults with type 2 diabetes

2024-09-11
The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D) [1]. Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight loss indicates that greater weight loss, better β-cell function, and a greater decrease in low-density lipoprotein cholesterol (LDL-C or “bad cholesterol”) during the first year of tirzepatide therapy are the most ...

Avian flu found in wastewater of 10 Texas cities through virome sequencing by researchers at UTHealth Houston and Baylor College of Medicine

Avian flu found in wastewater of 10 Texas cities through virome sequencing by researchers at UTHealth Houston and Baylor College of Medicine
2024-09-11
Avian influenza A(H5N1) virus, which spread to cattle and infected 14 people this year, was detected using virome sequencing in the wastewater of 10 Texas cities by researchers at UTHealth Houston and Baylor College of Medicine. The virome is the collection of viruses in a sample, in this case a wastewater sample. The information was published in the New England Journal of Medicine. Until March 2024, H5N1 had not been detected in 1,337 wastewater samples analyzed by the team. But from March 4 to July 15 (the end of data collection for this article), H5N1 was ...

Culturing muscle cells

Culturing muscle cells
2024-09-11
Harvard stem cell biologists have pioneered a groundbreaking 3D organoid culture method for generating large numbers of adult skeletal muscle satellite cells, also known as muscle stem cells, in vitro. The ability to efficiently make functional muscle stem cells in this way is expected to accelerate understanding of and treatments for disorders of skeletal muscle, including those that are neuromuscular in origin. The new technique, detailed in Nature Biotechnology, also provides a powerful tool for studying muscle biology. "People will be able to do all these engraftment and regeneration experiments because suddenly, you have millions of cells,” said co-author and Harvard research ...

ORNL debuts convergent manufacturing platform at IMTS 2024

ORNL debuts convergent manufacturing platform at IMTS 2024
2024-09-11
A new convergent manufacturing platform, developed in only five months at the Department of Energy’s Oak Ridge National Laboratory, is debuting at the International Manufacturing Technology Show, or IMTS, in Chicago, Sept. 9–12, 2024. The technology, called Future Foundries, opens the door for hundreds of thousands of small- and medium-sized companies to join the convergent manufacturing revolution, according to ORNL researchers. It is a cutting-edge platform that integrates multiple advanced manufacturing systems into a single, agile platform. “The democratization ...

New insights could help prevent psychosis relapses in youth and young adults

2024-09-11
New findings from McGill University researchers could help clinicians understand the course of delusions in youth and young adults that signal the need for a timely intervention to prevent a full relapse of psychosis. Delusions — strong beliefs that don't align with commonly accepted reality— are a defining symptom of psychosis but are not sufficiently understood. For the first time, researchers studied whether delusion themes, such as paranoia or grandiosity, stay the same or shift between psychotic episodes in youth and young adults undergoing early intervention treatment. The importance of timely ...

Biogeochemistry scientists from around the world, led by the ASC's Margenot, publish position paper on tackling “hidden” phosphorus

Biogeochemistry scientists from around the world, led by the ASCs Margenot, publish position paper on tackling “hidden” phosphorus
2024-09-11
As the world tries to mitigate agriculture’s effect on the environment, much of the story can be found in the soils, which stores and cycles nutrient elements of carbon, nitrogen, and phosphorus. Biogeochemistssuch as Andrew Margenot, Associate Director of the Agroecosystem Sustainability Center, are set to find answers, but for Margenot and other biogeochemistry experts who specialize in studying phosphorus cycling, the challenge is first being able to accurately measure where phosphorus has accumulated in the <100 years since humans began to increase ...

New, rare type of small cell lung cancer identified by MSK research team

New, rare type of small cell lung cancer identified by MSK research team
2024-09-11
A team of doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Their findings, which include a detailed analysis of the clinical and genetic features of the disease, also highlight vulnerabilities that could help doctors make better treatment decisions for people diagnosed with it. “It’s not every day you identify a new subtype of cancer,” says Natasha Rekhtman, MD, PhD, an MSK pathologist specializing in lung cancer and the first author of a paper published August 26 in Cancer Discovery presenting ...

LAST 30 PRESS RELEASES:

Workforce diversity is key to advancing One Health

Genome Research publishes a special issue on innovations in computational biology

A quick and easy way to produce anode materials for sodium-ion batteries using microwaves

‘Inside-out’ galaxy growth observed in the early universe

Protein blocking bone development could hold clues for future osteoporosis treatment

A new method makes high-resolution imaging more accessible

Tiny magnetic discs offer remote brain stimulation without transgenes

Illuminating quantum magnets: Light unveils magnetic domains

Different types of teenage friendships critical to wellbeing as we age, scientists find

Hawaii distillery project wins funding from Scottish brewing and distilling award

Trinity researchers find ‘natural killer’ cells that live in the lung are ready for a sugar rush

$7 Million from ARPA-H to tackle lung infections through innovative probiotic treatment

Breakdancers may risk ‘headspin hole’ caused by repetitive headspins, doctors warn

Don’t rely on AI chatbots for accurate, safe drug information, patients warned

Nearly $10M investment will expand and enhance stroke care in Minnesota, South Dakota

Former Georgia, Miami coach Mark Richt named 2025 Paul “Bear” Bryant Heart of a Champion

$8.1M grant will allow researchers to study the role of skeletal stem cells in craniofacial bone diseases and deformities

Northwestern to promote toddler mental health with $11.7 million NIMH grant

A new study finds that even positive third-party ratings can have negative effects

Optimizing inhibitors that fight antibiotic resistance

New Lancet Commission calls for urgent action on self-harm across the world

American Meteorological Society launches free content for weather enthusiasts with “Weather Band”

Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy

How your skin tone could affect your meds

NEC Society, Cincinnati Children's, and UNC Children’s announce NEC Symposium in Chicago

Extreme heat may substantially raise mortality risk for people experiencing homelessness

UTA professor earns NSF grants to study human-computer interaction

How playing songs to Darwin’s finches helped UMass Amherst biologists confirm link between environment and the emergence of new species

A holy grail found for catalytic alkane activation

Galápagos finches could be singing a different song after repeated drought—one that leads to speciation

[Press-News.org] Large-scale population analysis confirms reassuring safety profile of tirzepatide
Analysis of real-world evidence from the FDA adverse event reporting system database finds tirzepatide has similar gastrointestinal tolerability to other GLP-1 medications, without increased risk of diabetic retinopathy, medullary thyroid cancer, or pancr